Integrated Regional Laboratories Pathology Services, LLC
Integrated Regional Laboratories Pathology Services, LLC was paid $87K by Medicaid between Mar 2021 and Nov 2024, across 51 billing codes. Its largest line is U0002, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc — 20% of everything it billed.
ST PETERSBURG, FL 33710
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Florida
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 5,018 | $6K | |
| 2022 | 12,378 | $21K | |
| 2023 | 26,369 | $35K | |
| 2024incomplete | 21,104 | $25K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 20% | 995 | 811 | $17K |
| 80053 | Comprehensive metabolic panel | 12% | 9,099 | 5,202 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 9.9% | 1,280 | 1,156 | $9K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 9.8% | 5,478 | 2,435 | $8K |
| 84484 | 6.6% | 2,092 | 1,743 | $6K | |
| 85027 | 6.0% | 10,991 | 5,985 | $5K | |
| 84702 | 4.9% | 1,391 | 1,125 | $4K | |
| 87040 | 4.0% | 916 | 750 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.9% | 2,130 | 1,998 | $3K |
| 81025 | 3.1% | 1,727 | 1,551 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.9% | 1,278 | 1,154 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 1,540 | 948 | $2K |
39 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 736 | $1K |
| 83690 | 1.3% | 2,389 | $1K | |
| 83735 | 1.3% | 2,019 | $1K | |
| 81001 | 1.3% | 4,441 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.1% | 761 | $966.24 |
| 83880 | <1% | 514 | $758.62 | |
| 83605 | <1% | 713 | $665.65 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 971 | $581.42 |
| 87070 | <1% | 863 | $535.64 | |
| 85610 | <1% | 2,000 | $486.41 | |
| 87077 | <1% | 467 | $408.01 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 186 | $397.36 |
| 86850 | <1% | 765 | $391.86 | |
| 86900 | <1% | 1,896 | $389.20 | |
| 85730 | <1% | 814 | $367.65 | |
| 87210 | <1% | 1,232 | $365.03 | |
| 86901 | <1% | 1,897 | $358.63 | |
| 87186 | <1% | 254 | $344.97 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13 | $337.81 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 49 | $313.39 |
| 81003 | <1% | 1,551 | $272.06 | |
| 86880 | <1% | 210 | $259.43 | |
| 85379 | <1% | 322 | $147.90 | |
| 80076 | <1% | 81 | $64.70 | |
| 86592 | <1% | 259 | $53.27 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 27 | $35.51 |
| 87280 | <1% | 12 | $23.46 | |
| 80061 | Lipid panel | <1% | 14 | $20.78 |
| 87205 | <1% | 52 | $16.05 | |
| 87081 | <1% | 22 | $14.83 | |
| 85018 | <1% | 65 | $14.82 | |
| 82550 | <1% | 16 | $12.66 | |
| 84100 | <1% | 79 | $12.37 | |
| 85007 | <1% | 71 | $11.97 | |
| 86140 | <1% | 17 | $11.76 | |
| 85014 | <1% | 87 | $10.43 | |
| 85049 | <1% | 29 | $7.15 | |
| 85041 | <1% | 29 | $4.40 | |
| 85048 | <1% | 29 | $3.74 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.